LIXTE Biotechnology Expands Cancer Treatment Pipeline with Acquisition of Proton Therapy Innovator Liora Technologies

LIXTE Biotechnology Holdings Inc. (NASDAQ: LIXT) has expanded its cancer treatment pipeline through the acquisition of Liora Technologies, a company pioneering proton therapy systems for treating tumors across various cancer types. The acquisition makes Liora a wholly owned subsidiary of LIXTE and includes Liora's proprietary LiGHT System (Linac for Image Guided Hadron Therapy), which offers multiple advantages over existing proton therapy technologies. According to Professor Steve Myers, former Director of Accelerators and Technology at CERN, "The highly adaptable LiGHT System provides a proton beam allowing the delivery of very high dose rates to deep-seated tumors." This technology not only offers unique biological effects but also promises to significantly reduce installation costs and the number of treatment sessions required compared to current technologies.

The LiGHT System is expected to dramatically increase the number of patients that treatment centers can serve, addressing a critical access issue in cancer care. This acquisition comes as LIXTE continues to advance its clinical-stage pharmaceutical development, particularly its first-in-class lead clinical PP2A inhibitor, LB-100. According to extensive preclinical data available at https://www.lixte.com, LB-100 has demonstrated potential to significantly enhance chemotherapies and immunotherapies while improving outcomes for cancer patients. The company's approach represents a pioneering effort in the new field of cancer biology known as activation lethality, advancing a novel treatment paradigm supported by a comprehensive patent portfolio.

LIXTE is currently conducting proof-of-concept clinical trials for ovarian clear cell carcinoma and metastatic colon cancer, building on previous demonstrations that LB-100 is well-tolerated in cancer patients at doses associated with anti-cancer activity. The integration of Liora's proton therapy technology with LIXTE's pharmaceutical development creates a more comprehensive approach to cancer treatment. The full details of this strategic acquisition can be found at https://ibn.fm/W6gD5, while ongoing updates about LIXTE's developments are available through the company's newsroom at https://ibn.fm/LIXT. This combination of pharmaceutical innovation and advanced radiation therapy technology positions LIXTE to address multiple aspects of cancer treatment, potentially transforming patient care through both systemic and localized therapeutic approaches.

The acquisition represents a strategic expansion beyond LIXTE's core pharmaceutical focus, incorporating cutting-edge radiation technology that could complement its drug development pipeline. By reducing both the cost and duration of proton therapy treatments, the LiGHT System addresses significant barriers that have limited widespread adoption of proton therapy despite its clinical advantages. The technology's ability to deliver high dose rates to deep-seated tumors while minimizing damage to surrounding healthy tissue could make advanced radiation treatment more accessible to patients who might otherwise face limited options. This development occurs within a broader context of increasing integration between pharmaceutical and technological approaches to cancer treatment, reflecting a growing recognition that comprehensive cancer care requires multiple therapeutic modalities working in concert.